DS
PVLA

David Shaw’s Palvella Therapeutics PVLA Stock Holding History

David Shaw’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,667
Closed -$504K – 6021
2021
Q4 		$504K Buy
+1,667
New +$534K ﹤0.01% 4401
2021
Q3 		– Sell
-968
Closed -$296K – 5287
2021
Q2 		$296K Buy
968
+729
+305% +$160K ﹤0.01% 4286
2021
Q1 		$49K Buy
+239
New +$52.2K ﹤0.01% 3967
2020
Q3 		– Sell
-191
Closed -$47K – 4236
2020
Q2 		$47K Sell
191
-40
-17% -$9.35K ﹤0.01% 3920
2020
Q1 		$42K Sell
231
-148
-39% -$37.3K ﹤0.01% 3840
2019
Q4 		$110K Sell
379
-718
-65% -$199K ﹤0.01% 3868
2019
Q3 		$299K Buy
1,097
+15
+1% +$5.81K ﹤0.01% 3465
2019
Q2 		$407K Buy
1,082
+165
+18% +$49.2K ﹤0.01% 3169
2019
Q1 		$246K Buy
917
+293
+47% +$69.6K ﹤0.01% 3309
2018
Q4 		$133K Buy
624
+323
+107% +$100K ﹤0.01% 3611
2018
Q3 		$135K Buy
+301
New +$131K ﹤0.01% 3597

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's PVLA Position: Q1 2022 in Review

David Shaw sold out of Palvella Therapeutics (PVLA) in Q1 2022, closing a stake of 1,667 shares — an estimated $504K sold.

David Shaw first reported a position in PVLA in Q3 2018 and held it in 11 quarters. The position peaked at $504K in Q4 2021. 71 funds tracked by Wall St. Rank hold PVLA as of Q1 2022.

  • David Shaw reported no remaining Palvella Therapeutics position as of Q1 2022 after selling out during the quarter.
  • David Shaw sold 1,667 Palvella Therapeutics shares in Q1 2022, an estimated $504K.
  • David Shaw first reported a position in Palvella Therapeutics in Q3 2018 and held it in 11 quarters.
  • David Shaw's Palvella Therapeutics position peaked at $504K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.